These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 8702226

  • 1. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ, Codde JP, Van der Meide PH, Gray BN.
    Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
    [Abstract] [Full Text] [Related]

  • 2. Improved efficacy of doxorubicin by simultaneous treatment with interferon-gamma and interleukin-2.
    Lumsden AJ, Codde JP, Gray BN, van der Meide PH.
    In Vivo; 1992; 6(5):553-8. PubMed ID: 1457750
    [Abstract] [Full Text] [Related]

  • 3. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS, Ip G, Wright MA, Young MR.
    Cancer Res; 1995 Feb 15; 55(4):885-90. PubMed ID: 7850804
    [Abstract] [Full Text] [Related]

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 5. Prevention of myelosuppression does not improve the therapeutic efficacy of chemo-immunotherapy.
    Lumsden AJ, Codde JP, Gray BN, Van der Meide PH.
    Anticancer Res; 1992 Jun 15; 12(5):1725-9. PubMed ID: 1444239
    [Abstract] [Full Text] [Related]

  • 6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW, Li D, McQuone SJ, Ralston R.
    Laryngoscope; 2005 Mar 15; 115(3):391-404. PubMed ID: 15744147
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 8. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I, Chu TM.
    Mol Biother; 1992 Mar 01; 4(1):47-52. PubMed ID: 1627274
    [Abstract] [Full Text] [Related]

  • 9. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A, Forni G, Colombo MP.
    Folia Biol (Praha); 1994 Mar 01; 40(1-2):89-99. PubMed ID: 7525363
    [Abstract] [Full Text] [Related]

  • 10. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE, Yamada RE, Crystal RG, Korst RJ.
    J Thorac Cardiovasc Surg; 2004 Feb 01; 127(2):355-64. PubMed ID: 14762342
    [Abstract] [Full Text] [Related]

  • 11. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
    Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ.
    J Immunol; 1994 Aug 15; 153(4):1697-706. PubMed ID: 7913943
    [Abstract] [Full Text] [Related]

  • 12. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
    Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ.
    Cancer Res; 2011 Jul 15; 71(14):4809-20. PubMed ID: 21646474
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct 15; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 14. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 15. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E.
    Cancer Res; 2002 Oct 15; 62(20):5727-35. PubMed ID: 12384531
    [Abstract] [Full Text] [Related]

  • 16. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M, Bubeník J, Mikysková R, Mendoza L, Símová J, Bieblová J, Jandlová T, Jinoch P, Smahel M, Vonka V, Pajtasz-Piasecka E.
    Int J Oncol; 2003 Mar 15; 22(3):691-5. PubMed ID: 12579325
    [Abstract] [Full Text] [Related]

  • 17. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.
    Br J Cancer; 1999 Sep 15; 81(2):359-66. PubMed ID: 10496366
    [Abstract] [Full Text] [Related]

  • 18. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 15; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 19. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ.
    J Immunol; 1998 Jan 01; 160(1):334-44. PubMed ID: 9551989
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T, Konno-Takahashi N, Kasuya Y, Ogushi T, Nishimatsu H, Kitamura T.
    BJU Int; 2004 Jul 01; 94(1):171-6. PubMed ID: 15217455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.